Quoin Pharmaceuticals — Third Quarter 2026 Earnings Summary

Quoin Pharmaceuticals reported positive interim data from its Phase 2/3 study of QRX003 for Netherton Syndrome, achieving statistical significance for primary and key secondary endpoints in the first six participants. The company secured a private placement financing of up to $50.0 million and received FDA clearance for the first Investigational New Drug application for Peeling Skin Syndrome, along with Rare Pediatric Disease and Fast Track designations. Additionally, the European Medicines Agency granted Orphan Drug Designation for QRX003 in Peeling Skin Syndrome, and the firm advanced its QRX009 topical rapamycin platform toward clinical testing. For the third quarter ended September 30, 2026, the company reported a net loss of approximately $4.9 million and held $33.2 million in cash and marketable securities.